270 related articles for article (PubMed ID: 22573715)
1. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.
Fagan DH; Uselman RR; Sachdev D; Yee D
Cancer Res; 2012 Jul; 72(13):3372-80. PubMed ID: 22573715
[TBL] [Abstract][Full Text] [Related]
2. Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells.
Chan JY; LaPara K; Yee D
Oncogene; 2016 Aug; 35(32):4235-43. PubMed ID: 26876199
[TBL] [Abstract][Full Text] [Related]
3. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
4. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Fox EM; Miller TW; Balko JM; Kuba MG; Sánchez V; Smith RA; Liu S; González-Angulo AM; Mills GB; Ye F; Shyr Y; Manning HC; Buck E; Arteaga CL
Cancer Res; 2011 Nov; 71(21):6773-84. PubMed ID: 21908557
[TBL] [Abstract][Full Text] [Related]
5. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
6. Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.
Hawsawi Y; Humphries MP; Wright A; Berwick A; Shires M; Al-Kharobi H; El-Gendy R; Jove M; Twelves C; Speirs V; Beattie J
Oncotarget; 2016 May; 7(22):32129-43. PubMed ID: 27050076
[TBL] [Abstract][Full Text] [Related]
7. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
Vincent EE; Elder DJ; Curwen J; Kilgour E; Hers I; Tavaré JM
PLoS One; 2013; 8(6):e66963. PubMed ID: 23826179
[TBL] [Abstract][Full Text] [Related]
8. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
Knowlden JM; Hutcheson IR; Barrow D; Gee JM; Nicholson RI
Endocrinology; 2005 Nov; 146(11):4609-18. PubMed ID: 16037379
[TBL] [Abstract][Full Text] [Related]
10. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
11. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
Chong K; Subramanian A; Sharma A; Mokbel K
Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.
Browne BC; Crown J; Venkatesan N; Duffy MJ; Clynes M; Slamon D; O'Donovan N
Ann Oncol; 2011 Jan; 22(1):68-73. PubMed ID: 20647220
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Browne BC; Eustace AJ; Kennedy S; O'Brien NA; Pedersen K; McDermott MS; Larkin A; Ballot J; Mahgoub T; Sclafani F; Madden S; Kennedy J; Duffy MJ; Crown J; O'Donovan N
Breast Cancer Res Treat; 2012 Dec; 136(3):717-27. PubMed ID: 23117852
[TBL] [Abstract][Full Text] [Related]
16. A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.
Fan P; Agboke FA; Cunliffe HE; Ramos P; Jordan VC
Eur J Cancer; 2014 Nov; 50(16):2866-76. PubMed ID: 25204804
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.
Chakraborty A; Hatzis C; DiGiovanna MP
Breast Cancer Res Treat; 2017 May; 163(1):37-50. PubMed ID: 28236033
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
Zeng X; Zhang H; Oh A; Zhang Y; Yee D
Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
[TBL] [Abstract][Full Text] [Related]
19. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
[TBL] [Abstract][Full Text] [Related]
20. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
